Business
US Agreement and Proposed Placing of Shares
US Agreement and Proposed Placing of Shares.
About this update from Oxford Biomedica Plc
[{"type":"text","content":"\n \n \n \n RNS Number : 9648Z\n Oxford Biomedica PLC\n 28 January 2022\n \n \n \n \n THIS ANNOUNCEMENT, INCLUDING THE APPENDICES AND THE INFORMATION CONTAINED IN THEM, IS RESTRICTED AND IS NOT FOR RELEASE, PUBLICATION, DISTRIBUTION OR FORWARDING, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, AUSTRALIA, CANADA, THE REPUBLIC OF SOUTH AFRICA, JAPAN OR ANY OTHER JURISDICTION IN WHICH SUCH PUBLICATION, RELEASE OR DISTRIBUTION WOULD BE UNLAWFUL.\n \n \n FURTHER, THIS ANNOUNCEMENT IS FOR INFORMATION PURPOSES ONLY AND DOES NOT CONSTITUTE OR CONTAIN ANY INVITATION, SOLICITATION, RECOMMENDATION, OFFER OR ADVICE TO ANY PERSON TO SUBSCRIBE FOR, OTHERWISE ACQUIRE OR DISPOSE OF ANY SECURITIES IN OXFORD BIOMEDICA PLC OR ANY OTHER ENTITY IN ANY JURISDICTION. NEITHER THIS ANNOUNCEMENT NOR THE FACT OF ITS DISTRIBUTION SHALL FORM THE BASIS OF, OR BE RELIED ON IN CONNECTION WITH, ANY INVESTMENT DECISION IN RESPECT OF OXFORD BIOMEDICA PLC.\n \n \n THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION FOR THE PURPOSES OF ARTICLE 7 OF REGULATION (EU) 596/2014 AS IT FORMS PART OF UK DOMESTIC LAW BY VIRTUE OF THE EUROPEAN UNION (WITHDRAWAL) ACT 2018, AS AMENDED.\n \n \n \n LEI: \n 213800S1GVQNXQ15K851 \n \n For immediate release\n \n OXFORD BIOMEDICA PLC\n \n \n Oxford Biomedica broadens leading viral vector offerings by incorporating Homology's established AAV capabilities into a newly-formed AAV Manufacturing and Innovation Business in the US with Homology as 20% owner \n \n \n Proposed Placing to raise total gross proceeds of approximately £80 million\n \n \n Oxford, UK - 28 January 2022: Oxford Biomedica plc (LSE:OXB) (\"Oxford Biomedica\" or the \"Company\"), a leading cell and gene therapy group, is pleased to announce that it has entered into an agreement with Homology Medicines Inc. (Nasdaq:FIXX) (\"Homology\") pursuant to which Oxford Biomedica (US) Inc. (\"Oxford Biomedica US\") will acquire an 80 per cent. ownership interest in a newly formed AAV focused manufacturing and innovation business, Oxford Biomedica Solutions LLC (\"Oxford Biomedica Solutions\" or \"Oxford Biomedica Solutions' AAV Manufacturing and Innovation Business\"), at an implied pre-money Enterprise Value of approximately US$175 million (£131 million) (the \"Transaction\").\n \n In addition, Oxford Biomedica announces that it propos...